Resource Center
All the industry news you need is right here
Technology Frontiers | Accelerated Domestic Substitution of Medium-Borosilicate Glass Presents Opportunities for Structural Upgrades in the Pharmaceutical Glass Industry
Release time:
2022-01-10
In recent years, with the deepening implementation of associated review and approval policies and bioequivalence evaluations, China’s pharmaceutical glass industry has been undergoing profound transformation. Industry experts point out that the replacement of low-borosilicate glass with medium-borosilicate glass and the shift from imported to domestically produced products have become inevitable trends in the industry’s development.
According to forecasts by the China Pharmaceutical Packaging Association, the pharmaceutical glass market is expected to maintain a growth rate of 10%–15% in the coming years. By 2025, global annual demand for medium-borosilicate pharmaceutical glass tubes is projected to reach 500,000 metric tons, with China accounting for 200,000 metric tons. For a long time, the medium-borosilicate glass market has been dominated by three major overseas companies—Germany’s Schott, the U.S.’s Corning, and Japan’s NEG—leaving a significant supply gap in the domestic market.
However, positive changes have emerged on the Drug Evaluation Center’s (DEEC) registration platform for active pharmaceutical ingredients, excipients, and packaging materials under the National Medical Products Administration (NMPA). Data shows that among the 180 activated entries for borosilicate packaging materials, 126 are domestic products, accounting for 70% of the total. This indicates that domestic borosilicate packaging materials are gradually replacing imported ones, and some domestic pharmaceutical manufacturers have begun using domestic borosilicate packaging materials as substitutes for imported ones.
As a high-tech enterprise holding 26 patented technologies, Puyang Shixuan possesses comprehensive production capabilities and technical expertise in the field of borosilicate glass products. The company’s product range includes a full series of borosilicate glass products, such as pre-formed vials (1ml–100ml) and ampoules (1ml–20ml), which feature excellent water resistance, thermal shock resistance, freeze resistance, and precise dimensional tolerance control. These products are particularly suitable for the packaging needs of highly sensitive pharmaceuticals, such as vaccines, biologics, and blood products.
The company’s technical director stated: “We will continue to increase our investment in R&D. Leveraging our portfolio of 26 patented technologies, we will continuously enhance the quality stability and process sophistication of our borosilicate glass products. We are committed to providing pharmaceutical companies with higher-quality, safer domestic packaging solutions to support the self-reliance and control of the national pharmaceutical industry chain.”